5 Pharmaceutical Stocks to Buy Now According to Billionaire Kerr Neilson

2. Exscientia PLC (NASDAQ:EXAI)

Stake Value of Platinum Asset Management: $32,568,000

Percentage of Platinum Asset Management’s 13F Portfolio: 0.9%

Number of Hedge Fund Holders: 11

Exscientia PLC (NASDAQ:EXAI) is a leading artificial intelligence-driven pharmaceutical company involved in discovering, designing, and developing drugs. The company offers end-to-end AI solutions for target identification, drug candidate design, translational models, and patient selection. On March 23, 2022, Exscientia PLC (NASDAQ:EXAI) reported fourth-quarter 2021 revenues of $5.47 million.

Last October, BofA analyst Michael Ryskin initiated coverage of Exscientia PLC (NASDAQ:EXAI) with a Buy rating and a $27 price target. The analyst noted that using AI to develop drugs in a cost-effective way will significantly drive the growth of the stock.

Exscientia PLC (NASDAQ:EXAI) was spotted on 11 hedge fund portfolios at the end of the fourth quarter of 2021. The total stakes of these funds in the company came to $143.77 million. Of these, $32.56 million belonged to Platinum Asset Management. The investment covers 0.9% of Kerr Neilson’s Q4 2021 investment portfolio.